Abstract
Objective: The triple combination CFTR modulator therapy with elexacaftor/tezacaftor/ivacaftor (ETI) improves CFTR function and abnormalities in lung morphology, including airway mucus plugging as shown by improved ventilation and reduced mucus on MRI in CF patients with at least one F508del allele. However, the effects on sputum viscoelasticity, airway microbiome and inflammation have not been studied. The aim of this study was therefore to examine the effects of ETI on sputum viscoelasticity, airway microbiome and inflammation, and airway proteome in CF patients with one or two F508del alleles aged 12 years and older.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
